For Immediate Release - April 17, 2003

USC/Norris will use the Selenia in their Lee Breast Center, a sector of the facility designed exclusively for the detection and treatment of breast diseases. The Lee Breast Center provides a broad range of breast care patient services, including screening and risk assessment, diagnostic work-up, and treatment for early, advanced and metastatic breast cancer.

Commenting on the Selenia, Dr. Yuri Parisky, Director of breast-imaging services at the USC/Norris Lee Breast Center said, "We use LORAD M-IV screen-film mammography systems with HTC® Grids exclusively in our center and have been extraordinarily pleased with the image quality and performance of these systems. Based on clinical images I have seen that were produced by the Selenia, which is built on the M-IV platform, and Hologic's track record for delivering innovative technological advances in this field, I fully expect this system to perform head and shoulders above the digital mammography technologies that have been available up until this time. Our Center is committed to delivering the highest quality care to our patient population, and we chose the Selenia because we believe it will play a key role in helping us fulfill that commitment, now and in the future."

The Selenia system incorporates the Company's proprietary DirectRay® direct conversion digital image receptor manufactured by the Company's Direct Radiography division in Newark, Delaware. With this technology, amorphous selenium is used to directly convert x-rays to electronic signals, without first converting them to light, a step required by systems using indirect conversion technology. This direct conversion process preserves image sharpness by completely eliminating image degradation caused by light diffusion. The Selenia, which was cleared for marketing in the United States in October 2002, is the only FDA-approved system using this advanced direct conversion technology.

Jack Cumming, Hologic's Chairman and CEO said, "We are delighted that USC/Norris has become an integral part of Hologic's drive to make our digital mammography technology available to the largest possible number of women on a worldwide basis. Since we commercially introduced the Selenia systems in the US earlier this year, we have been very pleased with the interest shown from the breast imaging community and are gratified with the level of support we've seen for this exciting technology."

This News Release contains forward-looking information that involves risks and uncertainties, including statements about Hologic's and USC/Norris Comprehensive Cancer Center plans objectives, expectations and intentions. Such statements include, without limitation, statements regarding the anticipated performance of the Selenia full field digital mammography system and the anticipated benefits of those systems. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those anticipated. Factors that could cause actual results to materially differ include, without limitation: Hologic's substantial reliance on USC/Norris' efforts to make this relationship successful; uncertainties inherent in the development of new products and the enhancement of existing products, including technical and regulatory risks, cost overruns and delays; the risk that newly introduced products may contain undetected errors or defects or otherwise not perform as anticipated; the early stage of market development for digital x-ray products; delays in shipments or installation of products which may affect the timing the Company's recognition of revenue; manufacturing risks that may limit Hologic's ability to ramp-up commercial production of the Selenia, including Hologic's reliance on a single source of supply for some key components of its products as well as the need to comply with especially high standards for those components and in the manufacture of digital x-ray products in general; technical innovations that could render products marketed or under development by Hologic obsolete; competition; Hologic's ability to expand its direct sales and service team for both the near and longer-term to effectively implement its direct sales strategy; risks relating to compliance with financial covenants under Hologic's working capital financing and leases; and reimbursement policies for the use of Hologic's products. Other factors that could adversely affect Hologic's business and prospects are described in Hologic's filings with the Securities and Exchange Commission. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such statement is based.